Bioblast Pharma (ORPN) and MYOS (MYOS) Head to Head Analysis

Bioblast Pharma (NASDAQ:ORPN) and MYOS (NASDAQ:MYOS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Bioblast Pharma and MYOS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioblast Pharma N/A N/A N/A
MYOS -660.40% -86.64% -65.14%

Earnings & Valuation

This table compares Bioblast Pharma and MYOS’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bioblast Pharma N/A N/A -$5.94 million N/A N/A
MYOS $360,000.00 30.80 -$3.22 million ($0.45) -2.69

MYOS has higher revenue and earnings than Bioblast Pharma.

Institutional & Insider Ownership

4.5% of Bioblast Pharma shares are owned by institutional investors. Comparatively, 4.6% of MYOS shares are owned by institutional investors. 47.3% of MYOS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Bioblast Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, MYOS has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Bioblast Pharma and MYOS, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioblast Pharma 0 0 0 0 N/A
MYOS 0 0 0 0 N/A

About Bioblast Pharma

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company has a collaboration with Team Sanfilippo to evaluate Trehalose for the treatment of sanfilippo syndrome. Bioblast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.

About MYOS

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.